{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T23:15:40Z","timestamp":1769642140616,"version":"3.49.0"},"reference-count":37,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2011,9,29]],"date-time":"2011-09-29T00:00:00Z","timestamp":1317254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Paediatrica"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Off\u2010label intravitreal use of the vascular endothelial growth factor (VEGF) antibody bevacizumab for retinopathy of prematurity (ROP) increases despite lack of studies on safety, pharmacokinetics and dosage in developing individuals. Systemic absorption has been considered negligible. A literature search was performed with emphasis on potential adverse systemic effects in developing individuals.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold>Intravitreal bevacizumab enters the general circulation, suppresses plasma VEGF levels and remains in the blood for more than 8\u2003weeks in primates. Possible adverse effects on VEGF\u2010dependent development must be considered.<\/jats:p>","DOI":"10.1111\/j.1651-2227.2011.02445.x","type":"journal-article","created":{"date-parts":[[2011,9,29]],"date-time":"2011-09-29T05:48:23Z","timestamp":1317275303000},"page":"1523-1527","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment \u2013 a review"],"prefix":"10.1111","volume":"100","author":[{"given":"Anna\u2010Lena","family":"H\u00e5rd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Hellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,9,29]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1100248"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.3129\/i10-067"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.3129\/i10-027"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"e_1_2_8_6_2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3565(24)37962-5","article-title":"Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor","volume":"288","author":"Lin YS","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2003-0027"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.585394"},{"key":"e_1_2_8_9_2","doi-asserted-by":"crossref","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery RL","year":"2006","journal-title":"Ophthalmology"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200603000-00005"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.128371"},{"issue":"2","key":"e_1_2_8_12_2","first-page":"F240","article-title":"Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney","volume":"268","author":"Simon M","year":"1995","journal-title":"Am J Physiol"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17423"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-3782(86)90092-7"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000101344"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm721"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e3181ccc9a9"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-004-8272-2"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2055"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1242\/dev.126.6.1149"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/9467"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707330"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000315617"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4425"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.01.017"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-3148"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200603000-00001"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200603000-00002"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-0828"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2871"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4140"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-1171"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.03.007"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6742"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181e46ad8"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.08.050"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S11650"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-0601"}],"container-title":["Acta Paediatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1651-2227.2011.02445.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1651-2227.2011.02445.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/j.1651-2227.2011.02445.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1651-2227.2011.02445.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T05:46:33Z","timestamp":1741758393000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1651-2227.2011.02445.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,29]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1111\/j.1651-2227.2011.02445.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1651-2227.2011.02445.x","archive":["Portico"],"relation":{},"ISSN":["0803-5253","1651-2227"],"issn-type":[{"value":"0803-5253","type":"print"},{"value":"1651-2227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,29]]},"assertion":[{"value":"2011-09-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}